Drug Development
Regimens combining antisense molecules with other drugs optimize outcomes
Published in Gene Therapy Weekly, February 3rd, 2005
"Targeting unique mRNA molecules using antisense approaches, based on sequence specificity of double-stranded nucleic acid interactions should, in theory, allow for design of drugs with high specificity for intended targets. Antisense-induced degradation or inhibition of translation of a target mRNA is potentially capable of inhibiting the expression of any target protein. In fact, a large number of proteins of widely varied character have been successfully down-regulated using an assortment of antisense-based approaches," researchers in Canada report.
"The most prevalent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-02-03)
More Articles from Gene Therapy Weekly
- Bladder Cancer
Pretreatment compounds augment adenovirus-based transfection of the bladder - Breast Cancer
Mammaglobin-1 promoter enhances the transfection of mammary tumor cells - Drug Delivery
High-affinity antibody steers therapy to hepatocellular carcinoma - Drug Development
Hybrid viral vectors generate site-specific gene incorporation - Glioma
Antisense treatment combats orthotopic brain tumors in rodent models - Nasopharyngeal Cancer
Findings describe new data in nasopharyngeal cancer research - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
